文献速递核素与放射性配体治疗肿瘤 PET/CT

皮质类固醇治疗对DLBCL中CXCR4表达的影响

Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
PubMed 文献 · EJNMMI Res · 2023-05-10

本研究在多种DLBCL细胞系及人T细胞淋巴瘤细胞系Jurkat中,观察地塞米松和泼尼松龙对CXCR4表面表达的影响,并用[125I]CPCR4.3结合实验及OCI-LY1荷瘤NSG小鼠[68Ga]PentixaTher生物分布验证。体外显示细胞系依赖的CXCR4上调,OCI-LY1体内肿瘤摄取在治疗组为21.0±5.5%iD/g,对照组为9.2±2.8%iD/g,作者认为皮质类固醇成分不导致CXCR4下调,可能有益。

要点

  • 地塞米松和泼尼松龙在部分DLBCL细胞系中引起CXCR4表面表达上调1.5至3.5倍,Jurkat、Daudi和SUDHL-8细胞系无变化。
  • OCI-LY1荷瘤小鼠经地塞米松治疗后肿瘤[68Ga]PentixaTher摄取为21.0±5.5%iD/g,未治疗组为9.2±2.8%iD/g。
  • 作者认为[177Lu]Lu-PentixaTher RLT前稳定化疗中的皮质类固醇成分不导致CXCR4下调,可能有益。

核心结论

  • 皮质类固醇治疗(地塞米松/泼尼松龙)在体外以高度细胞系依赖的方式一致诱导DLBCL细胞CXCR4表达上调。
  • 对地塞米松诱导CXCR4上调最明显的OCI-LY1细胞系,体外结果被体内生物分布研究证实。
  • 作者认为至少[177Lu]Lu-PentixaTher RLT前DLBCL患者稳定化疗方案中的皮质类固醇成分不导致分子靶点CXCR4下调,甚至可能有益。
  • 作者指出需进一步研究其他常用化疗药物是否及在多大程度上影响DLBCL的CXCR4表达,以确保[177Lu]Lu/[90Y]Y-PentixaTher RLT前选择合适的治疗方案。

研究设计与样本

  • 体外实验使用DLBCL细胞系Daudi、OCI-LY1、SUDHL-4、SUDHL-5、SUDHL-6、SUDHL-8及人T细胞淋巴瘤细胞系Jurkat,分别与地塞米松(0.5和5 µM)及泼尼松龙(5和50 µM)孵育2小时和24小时。
  • 通过流式细胞术评估细胞CXCR4表面表达调制,并与未处理细胞比较,同时用[125I]CPCR4.3进行放射性配体结合实验。
  • 体内实验对OCI-LY1荷瘤NSG小鼠腹腔注射地塞米松50 µg/只(每日一次,共6天),随后进行[68Ga]PentixaTher生物分布研究(注射后1小时),比较治疗组(n=5)与未治疗组(n=5)。

主要发现

  • 体外实验中,地塞米松和泼尼松龙处理均观察到强烈的细胞系依赖性CXCR4上调,高剂量与低剂量之间差异可忽略。
  • Jurkat、Daudi和SUDHL-8细胞中CXCR4表达保持不变,流式细胞术显示SUDHL-5 < SUDHL-4/-6 < OCI-LY1的CXCR4细胞表面表达较未处理细胞增加1.5至3.5倍。
  • CXCR4表达增加也反映在相应增强的[125I]CPCR4.3蓄积中,流式细胞术与放射性配体结合数据呈线性相关。
  • 体内地塞米松治疗导致所有器官中[68Ga]PentixaTher摄取普遍增加,归因于血液中示踪剂浓度较高。
  • 治疗组OCI-LY1肿瘤中[68Ga]PentixaTher摄取为21.0±5.5%iD/g,未治疗组为9.2±2.8%iD/g,治疗组肿瘤/背景比值更高。

局限性

  • 作者指出需进一步研究其他常用化疗药物是否及在多大程度上影响DLBCL的CXCR4表达,以确保[177Lu]Lu/[90Y]Y-PentixaTher RLT前选择合适的治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CXCR4-targeted radioligand therapy (RLT) with [177Lu]Lu/[90Y]Y-PentixaTher has recently evolved as a promising therapeutic option for patients with advanced hematological cancers. Given their advanced disease stage, most patients scheduled for PentixaTher RLT require concomitant or bridging chemotherapy to prevent intermittent tumor progression. These (mostly combination) therapies may cause significant downregulation of tumoral CXCR4 expression, challenging the applicability of PentixaTher RLT. This study therefore aimed at investigating the influence of corticosteroids, a central component of these chemotherapies, on CXCR4 regulation in diffuse large B cell lymphoma (DLBCL). METHODS: Different DLBCL cell lines (Daudi, OCI-LY1, SUDHL-4, -5-, -6 and -8) as well as the human T-cell lymphoma cell line Jurkat were incubated with Dexamethasone (Dex; 0.5 and 5 µM, respectively) and Prednisolone (Pred; 5 and 50 µM, respectively) for different time points (2 h, 24 h). Treatment-induced modulation of cellular CXCR4 surface expression was assessed via flow cytometry (FC) and compared to untreated cells. A radioligand binding assay with [125I]CPCR4.3 was performed in parallel using the same cells. To quantify potential corticosteroid treatment effects on tumoral CXCR4 expression in vivo, OCI-LY1 bearing NSG mice were injected 50 µg Dex/mouse i.p. (daily for 6 days). Then, a biodistribution study (1 h p.i.) using [68Ga]PentixaTher was performed, and tracer biodistribution in treated (n = 5) vs untreated mice (n = 5) was compared. RESULTS: In the in vitro experiments, a strongly cell line-dependent upregulation of CXCR4 was observed for both Dex and Pred treatment, with negligible differences between the high and low dose. While in Jurkat, Daudi and SUDHL-8 cells, CXCR4 expression remained unchanged, a 1.5- to 3.5-fold increase in CXCR4 cell surface expression was observed for SUDHL-5 < SUDHL-4 /-6 < OCI-LY1 via FC compared to untreated cells. This increase in CXCR4 expression was also reflected in correspondingly enhanced [125I]CPCR4.3 accumulation in treated cells, with a linear correlation between FC and radioligand binding data. In vivo, Dex treatment led to a general increase of [68Ga]PentixaTher uptake in all organs compared to untreated animals, as a result of a higher tracer concentration in blood. However, we observed an overproportionally enhanced [68Ga]PentixaTher uptake in the OCI-LY1 tumors in treated (21.0 ± 5.5%iD/g) vs untreated (9.2 ± 2.8%iD/g) mice, resulting in higher tumor-to-background ratios in the treatment group. CONCLUSION: Overall, corticosteroid treatment (Dex/Pred) consistently induced an upregulation of CXCR4 expression DBLCL cells in vitro, albeit in a very cell line-dependent manner. For the cell line with the most pronounced Dex-induced CXCR4 upregulation, OCI-LY1, the in vitro findings were corroborated by an in vivo biodistribution study. This confirms that at least the corticosteroid component of stabilizing chemotherapy regimens in DLBCL patients prior to [177Lu]Lu-PentixaTher RLT does not lead to downregulation of the molecular target CXCR4 and may even have a beneficiary effect. However, further studies are needed to investigate if and to what extent the other commonly used chemotherapeutic agents affect CXCR4 expression on DLBCL to ensure the choice of an appropriate treatment regimen prior to [177Lu]Lu/[90Y]Y-PentixaTher RLT.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Martin S, Viertl D, Janz A, et al. Influence of corticosteroid treatment on CXCR4 expression in DLBCL. EJNMMI Res. 2023. PMID: 37162652. doi:10.1186/s13550-023-00993-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。